PubMed:25305591 / 904-1319 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T5","span":{"begin":0,"end":415},"obj":"Sentence"},{"id":"T5","span":{"begin":0,"end":415},"obj":"Sentence"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"PubMed_ArguminSci","denotations":[{"id":"T4","span":{"begin":0,"end":415},"obj":"DRI_Outcome"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"TEST-DiseaseOrPhenotypicFeature","denotations":[{"id":"T4","span":{"begin":138,"end":141},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":247,"end":262},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"#label","subj":"T4","obj":"D004681"},{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"TEST-OrganismTaxon","denotations":[{"id":"T3","span":{"begin":29,"end":33},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":164,"end":168},"obj":"OrganismTaxon"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"Test-SequenceVariant","denotations":[{"id":"T1","span":{"begin":49,"end":65},"obj":"SequenceVariant"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"Test-GeneOrGeneProduct","denotations":[{"id":"T13","span":{"begin":61,"end":66},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":81,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":274,"end":279},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":281,"end":285},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":287,"end":292},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":304,"end":309},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":330,"end":357},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":359,"end":364},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":366,"end":370},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":376,"end":380},"obj":"GeneOrGeneProduct"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"Test-merged-2","denotations":[{"id":"T6647","span":{"begin":49,"end":65},"obj":"SequenceVariant"},{"id":"T13","span":{"begin":61,"end":66},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":81,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":274,"end":279},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":281,"end":285},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":287,"end":292},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":304,"end":309},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":330,"end":357},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":359,"end":364},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":366,"end":370},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":376,"end":380},"obj":"GeneOrGeneProduct"},{"id":"T3340","span":{"begin":29,"end":33},"obj":"OrganismTaxon"},{"id":"T98021","span":{"begin":164,"end":168},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":138,"end":141},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":247,"end":262},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"#label","subj":"T4","obj":"D004681"},{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}

{"project":"Test-merged","denotations":[{"id":"T5","span":{"begin":247,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":138,"end":141},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T98021","span":{"begin":164,"end":168},"obj":"OrganismTaxon"},{"id":"T3340","span":{"begin":29,"end":33},"obj":"OrganismTaxon"},{"id":"T22","span":{"begin":376,"end":380},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":366,"end":370},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":359,"end":364},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":330,"end":357},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":304,"end":309},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":287,"end":292},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":281,"end":285},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":274,"end":279},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":81,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":61,"end":66},"obj":"GeneOrGeneProduct"},{"id":"T6647","span":{"begin":49,"end":65},"obj":"SequenceVariant"}],"attributes":[{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"},{"id":"A4","pred":"#label","subj":"T4","obj":"D004681"}],"text":"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-α, IL-6, IFN-γ (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFβ, and IL-4 (Th2)) in the CNS and lymph nodes."}